15+
參考文獻
里程碑
經典論文
2025
最新更新
1
Sung H, Ferlay J, Siegel RL, et al.. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.
2021
2
Bray F, Laversanne M, Weiderpass E, Soerjomataram I. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263.
2024
3
Kratzer TB, Mazzitelli N, Star J, et al.. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians. 2025;75(6):485-497.
2025
4
Epstein JI, Egevad L, Amin MB, et al.. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology. 2016;40(2):244-252.
2016
5
Mottet N, van den Bergh RCN, Briers E, et al.. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Urology. 2024;85(2):159-182.
2024
6
Sweeney CJ, Chen YH, Carducci M, et al.. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (CHAARTED). New England Journal of Medicine. 2015;373(8):737-746.
2015
7
Fizazi K, Tran N, Fein L, et al.. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE). New England Journal of Medicine. 2017;377(4):352-360.
2017
8
Davis ID, Martin AJ, Stockler MR, et al.. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer (ENZAMET). New England Journal of Medicine. 2019;381(2):121-131.
2019
9
Smith MR, Hussain M, Saad F, et al.. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer (ARASENS). New England Journal of Medicine. 2022;386(12):1132-1142.
2022
10
Sartor O, de Bono J, Chi KN, et al.. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION). New England Journal of Medicine. 2021;385(12):1091-1103.
2021
11
de Bono J, Mateo J, Fizazi K, et al.. Olaparib for Metastatic Castration-Resistant Prostate Cancer (PROfound). New England Journal of Medicine. 2020;382(22):2091-2102.
2020
12
Tannock IF, de Wit R, Berry WR, et al.. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer (TAX 327). New England Journal of Medicine. 2004;351(15):1502-1512.
2004
13
de Bono JS, Oudard S, Ozguroglu M, et al.. Prednisone plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer (TROPIC). Lancet. 2010;376(9747):1147-1154.
2010
14
Fizazi K, Foulon S, Carles J, et al.. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1). Lancet. 2022;399(10336):1695-1707.
2022
15
Hamdy FC, Donovan JL, Lane JA, et al.. 15-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT). New England Journal of Medicine. 2023;388(17):1547-1558.
2023
引用說明
本書中的參考文獻採用作者-年份格式引用，例如 (Author, Year)。 所有引用的文獻均經過同行評審，並來自權威的醫學期刊和臨床指南。 如需查閱原始文獻，請點擊 DOI 或 PMID 連結。